Videos

Barnes reviews 3-year VIVID-2 data showing durable remission, steroid-free control, and stable safety with mirikizumab in moderate-to-severe Crohn’s disease.

This segment of the latest Skin of Color Savvy episode highlights discoid lupus in skin of color, housing barriers, and Medicaid navigation.

Targeting CD28 and CD154 pathways, dual blockade with belatacept and dazodalibep offers a new mechanistic approach in kidney transplant care.

Anouti outlines why early bilirubin testing and emerging serum markers are key to improving prognosis in biliary atresia.

Marsan and Santi discuss their recent study highlighting the need for lower LVESVi thresholds in aortic valve surgery in women to reduce mortality outcomes.

New data show limited uptake of SBS-specific ICD-10 codes, raising concerns about misclassification and the true burden of disease.

Navar discusses the positive data from the phase 3 trial and emphasizes substantial treatment adherence throughout the 52-week period.

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

Stocker discusses the potential for a wearable patch to continuous drug measurement of vancomycin, especially in pediatric patients and outpatient settings.

Diabetes Dialogue Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the patient awareness motivation behind Novo Nordisk’s recent announcement.

Rizik and Morris discuss the Heartflow PCI Navigator and its promising implications for patients – and how they manage that excitement while waiting for trial data.

This Skin of Color Savvy episode featured Abrahem Kazemi, MD, who speaks on several notable experiences he had as a dermatologist.

Stocker discusses findings from a pilot phase trial with clinical insight into a wearable patch for continuous drug measurement of vancomycin.

This Heart Failure Awareness Week, revisit recent advancements and scope out the future of heart failure care with HCPLive.

This segment of an interview from Maui Derm Hawaii, featuring Mark Kaufmann, MD, highlights key advice on AI scribe use and billing effectiveness in dermatology practices.

Younossi emphasizes the need for NIT-based risk stratification for MASLD, citing his research supporting their widespread adoption across clinical settings.

Valenta discusses how seasonal allergen exposure selectively boosts IgE production through plasmablast recall, without a coordinated IgG response.

Downey discusses the recent discovery of influenza’s interaction with the interferon 1 pathway, as well as a hypothetical method for preventing it.

The free, user-friendly calculator provides a 6-year lung cancer risk estimate to help patients and clinicians assess screening eligibility.

Younossi explains the growing interest in NITs for MASLD and reviews his research on their performance in age, diabetes, and obesity subgroups.

Rizik and Morris discuss the Heartflow PCI Navigator, which analyzes CT scans to generate 3D models of calcium blockages ahead of procedures.

Desai discusses his recent observational cohort study indicating finerenone’s substantial reduction of heart failure exacerbation risk in patients with HFpEF.

This interview with Marghoob was held on-site at Maui Derm, highlighting tips on dermoscopy and skin cancer detection from Marghoob’s workshop presentation.

Wu discusses his recent study spotlighting food source and quality as a more significant influence on CHD risk compared to simply cutting carbs or fat.

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes.

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

In the opening segment of this special report, panelists discuss updated anaphylaxis guidelines and early management priorities.